Vicapsys Life Sciences, Inc. (VICP)

Market Cap	4.86M
Revenue (ttm)	n/a
Net Income	-1.35M
EPS	-0.04
Shares Out	32.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Average Volume	697
Open	0.1500
Previous Close	n/a
Day's Range	0.1500 - 0.1500
52-Week Range	0.1500 - 1.7500
Beta	453,881.05
RSI	40.66
Earnings Date	Apr 16, 2026

About Vicapsys Life Sciences

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company’s product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics Internati...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 2
• Stock Exchange: OTCMKTS
• Ticker Symbol: VICP